An inflammation resolution–promoting intervention prevents atrial fibrillation caused by left ventricular dysfunction
Cardiovascular Research · 2024
DOI: 10.1093/cvr/cvad175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, 2024. Verfasst von Roddy Hiram und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Montreal Heart Institute (MHI), Université de Montréal, 5000 Belanger Street, Montreal, Quebec, CanadaH1T 1C8. Hauptthemen laut MEDLINE: Atrial Fibrillation, Atrial Remodeling, Myocardial Infarction, Cardiomyopathies. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR, Canadian Foundation for Innovation, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Aims
Recent studies suggest that bioactive mediators called resolvins promote an active resolution of inflammation. Inflammatory signalling is involved in the development of the substrate for atrial fibrillation (AF). The aim of this study is to evaluate the effects of resolvin-D1 on atrial arrhythmogenic remodelling resulting from left ventricular (LV) dysfunction induced by myocardial infarction (MI) in rats. Methods and results MI was produced by left anterior descending coronary artery ligation. Intervention groups received daily intraperitoneal resolvin-D1, beginning before MI surgery (early-RvD1) or Day 7 post-MI (late-RvD1) and continued until Day 21 post-MI. AF vulnerability was evaluated by performing an electrophysiological study. Atrial conduction was analysed by using optical mapping. Fibrosis was quantified by Masson’s trichrome staining and gene expression by quantitative polymerase chain reaction and RNA sequencing. Investigators were blinded to group identity. Early-RvD1 significantly reduced MI size (17 ± 6%, vs. 39 ± 6% in vehicle-MI) and preserved LV ejection fraction; these were unaffected by late-RvD1. Transoesophageal pacing induced atrial tachyarrhythmia in 2/18 (11%) sham-operated rats, vs. 18/18 (100%) MI-only rats, in 5/18 (28%, P < 0.001 vs. MI) early-RvD1 MI rats, and in 7/12 (58%, P < 0.01) late-RvD1 MI rats. Atrial conduction velocity significantly decreased post-MI, an effect suppressed by RvD1 treatment. Both early-RvD1 and late-RvD1 limited MI-induced atrial fibrosis and prevented MI-induced increases in the atrial expression of inflammation-related and fibrosis-related biomarkers and pathways.
Conclusions
RvD1 suppressed MI-related atrial arrhythmogenic remodelling. Early-RvD1 had MI sparing and atrial remodelling suppressant effects, whereas late-RvD1 attenuated atrial remodelling and AF promotion without ventricular protection, revealing atrial-protective actions unrelated to ventricular function changes. These results point to inflammation resolution–promoting compounds as novel cardio-protective interventions with a particular interest in attenuating AF substrate development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Montreal Heart Institute (MHI), Université de Montréal, 5000 Belanger Street, Montreal, Quebec, CanadaH1T 1C8.
- Department of Pharmacology and Therapeutics, McGill University, 3655 Prom. Sir William Osler, Montreal, Canada H3G 1Y6.
- Institute of Pharmacology, West German Heart and Vascular Center, Faculty of Medicine, University Duisburg-Essen, Hufelandstr 55, Essen, Germany D-45122.
- Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Norregade 10 P.O. Box 2177, Copenhagen, Denmark.
- Department of Thoracic and Cardiovascular Surgery, West German Heart and Vascular Center Essen, University Hospital Essen, Hufelanstr 55, Essen, Germany 45122.
- Department of Physiology and Biochemistry, Faculty of Medicine, Jordan University of Science and Technology, P.O. Box 3030 Irbid, Jordan 22110.
ORCID-Profile: Roddy Hiram, Arnela Saljic, Jean-Claude Tardif, Dobromir Dobrev, Stanley Nattel
Förderung
- CIHR
- Canadian Foundation for Innovation
- Canadian Institutes of Health Research
- Heart and Stroke Foundation of Canada
Zitieren
APA
Hiram, R., Xiong, F., Naud, P., Xiao, J., Sosnowski, D. K., Le Quilliec, E., Saljic, A., Abu-Taha, I. H., Kamler, M., LeBlanc, C. A., Al-U'Datt, D. G. F., Sirois, M. G., Hebert, T. E., Tanguay, J. F., Tardif, J. C., Dobrev, D., & Nattel, S. (2024). An inflammation resolution–promoting intervention prevents atrial fibrillation caused by left ventricular dysfunction. Cardiovascular Research. https://doi.org/10.1093/cvr/cvad175
Vancouver
Hiram R, Xiong F, Naud P, Xiao J, Sosnowski DK, Le Quilliec E, et al. An inflammation resolution–promoting intervention prevents atrial fibrillation caused by left ventricular dysfunction. Cardiovascular Research. 2024. doi:10.1093/cvr/cvad175
BibTeX
@article{Hiram2024,
author = {Hiram, Roddy and Xiong, Feng and Naud, Patrice and Xiao, Jiening and Sosnowski, Deanna K and Le Quilliec, Ewen and Saljic, Arnela and Abu-Taha, Issam H and Kamler, Markus and LeBlanc, Charles-Alexandre and Al-U'Datt, Doa'a G F and Sirois, Martin G and Hebert, Terence E and Tanguay, Jean-François and Tardif, Jean-Claude and Dobrev, Dobromir and Nattel, Stanley},
title = {An inflammation resolution–promoting intervention prevents atrial fibrillation caused by left ventricular dysfunction},
journal = {Cardiovascular Research},
year = {2024},
doi = {10.1093/cvr/cvad175}
}
EUVIMED